Leerink analyst David Larsen is "incrementally" more cautious on athenahealth (ATHN) following a survey of 40 physician practices. While the analyst believes the company has an "excellent" model and management team, he expects the replacement market to slow down, and the longer-term doc-add and bookings growth comps to become more challenging. Larsen added that the data is also positive for Cerner (CERN) and Epic, negative for Quality Systems (QSII), and slightly positive for Allscripts (MDRX). The analyst reiterates a Market Perform and $150 price target on athenahealth's shares.